Global Information
회사소개 | 문의 | 비교리스트

EpiCast Report : 2형 당뇨병의 역학적 예측(-2026년)

Type 2 Diabetes: Epidemiology Forecast to 2028

리서치사 GlobalData
발행일 2020년 01월 상품코드 274255
페이지 정보 영문 50 Pages 배송안내
가격
US $ 3,995 ₩ 5,675,000 PDF (Single user license) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 7,990 ₩ 11,350,000 PDF (Site license) help
동일 사업장 내 모든 분들이 공유하여 사용할 수 있습니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 2부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 11,985 ₩ 17,025,000 PDF (Global license) help
동일 기업의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없으며, 해외 사업장 및 100% 자회사는 동일 기업으로 간주됩니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 10부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.


EpiCast Report : 2형 당뇨병의 역학적 예측(-2026년) Type 2 Diabetes: Epidemiology Forecast to 2028
발행일 : 2020년 01월 페이지 정보 : 영문 50 Pages

본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

당뇨병은 세계에서 가장 많이 볼 수 있는 비전염성 질환으로, 세계 전체 환자 중 90% 이상이 2형 당뇨병입니다. 세계 주요 7개국(미국, 프랑스, 독일, 이탈리아, 스페인, 영국, 일본)의 2형 당뇨병 진단 환자수는 2016년 약 5,600만명에서 향후 10년 이내에 약 7,782만명에 이를 전망으로. 3.88%의 연간 성장률이 예측됩니다.

세계 주요 7개국의 2형 당뇨병(Type 2 Diabetes)에 대해 조사 분석했으며, 질환의 배경, 위험인자와 병존 질환, 세계 동향, 역학 예측 등의 정보를 정리하여 전해드립니다.

제1장 목차

제2장 주요 요약

제3장 역학

  • 질환의 배경
  • 위험인자와 병존 질환
  • 세계 동향
  • 예측 방법
    • 이용한 정보 출처
    • 이용하지 않은 정보 출처
    • 예측 전제조건과 방법
  • 2형 당뇨병 역학 예측
    • 2형 당뇨병 진단 환자수
    • 2형 당뇨병 진단 환자수(연령별)
    • 2형 당뇨병 진단 환자수(성별)
    • 2형 당뇨병 진단 환자수(연령 표준화)
  • 논의
    • 역학 예측에 관한 고찰
    • 분석의 한계
    • 분석의 강점

제4장 부록

도표

LSH 17.08.18

List of Tables

  • Table 1: Summary of Newly Added Data Types
  • Table 2: Summary of Updated Data Types
  • Table 3: Risk Factors and Comorbidities for T2D

List of Figures

  • Figure 1: 9MM, Diagnosed Prevalent Cases of T2D, Both Sexes, All Ages, N, 2018 and 2028
  • Figure 2: 9MM, Diagnosed Prevalence of T2D (%), Men, All Ages, 2018
  • Figure 3: 9MM, Diagnosed Prevalence of T2D (%), Women, All Ages, 2018
  • Figure 4: 9MM, Sources Used and Not Used to Forecast Diagnosed Prevalent Cases of T2D
  • Figure 5: 9MM, Sources Used to Forecast the Prevalent Cases of CKD Among the Diagnosed Prevalent Cases of T2D
  • Figure 6: 9MM, Sources Used to Forecast the Prevalent Cases of CVD Among the Diagnosed Prevalent Cases of T2D
  • Figure 7: 9MM, Sources Used to Forecast the Prevalent Cases of Obesity Among the Diagnosed Prevalent Cases of T2D
  • Figure 8: 9MM, Sources Used to Forecast the Prevalent Cases of Hypertension Among the Diagnosed Prevalent Cases of T2D
  • Figure 9: 9MM, Sources Used to Forecast the Prevalent Cases of Dyslipidemia Among the Diagnosed Prevalent Cases of T2D
  • Figure 10: 9MM, Sources Used to Forecast the Prevalent Cases of Atherosclerosis Among the Diagnosed Prevalent Cases of T2D
  • Figure 11: 9MM, Diagnosed Prevalent Cases of T2D, Both Sexes, All Ages, N, 2018
  • Figure 12: 9MM, Age-Specific Diagnosed Prevalent Cases of T2D, Both Sexes, N, 2018
  • Figure 13: 9MM, Sex-Specific Diagnosed Prevalent Cases of T2D, All Ages, N, 2018
  • Figure 14: 9MM, Prevalent Cases of CKD Among the Diagnosed Prevalent Cases of T2D, Both Sexes, All Ages, N, 2018
  • Figure 15: 9MM, Prevalent Cases of CVD Among the Diagnosed Prevalent Cases of T2D, Both Sexes, All Ages, N, 2018
  • Figure 16: 9MM, Prevalent Cases of Obesity Among the Diagnosed Prevalent Cases of T2D, Both Sexes, All Ages, N, 2018
  • Figure 17: 9MM, Prevalent Cases of Hypertension Among the Diagnosed Prevalent Cases of T2D, Both Sexes, All Ages, N, 2018
  • Figure 18: 9MM, Diagnosed Prevalent Cases of Dyslipidemia Among the Diagnosed Prevalent Cases of T2D, Both Sexes, All Ages, N, 2018
  • Figure 19: 9MM, Prevalent Cases of Atherosclerosis Among the Diagnosed Prevalent Cases of T2D, Both Sexes, All Ages, N, 2018

Type 2 diabetes (T2D), formerly known as non-insulin-dependent diabetes mellitus or adult-onset diabetes mellitus, is a chronic disorder of glucose equilibrium that results from the body's inability to make use of available insulin along with relative insulin deficiency (World Health Organization, 2016a). T2D constitutes approximately 90-95% of all diabetes cases around the world, while type 1 diabetes (T1D) and gestational diabetes make up the remaining 5-10% of the cases (International Diabetes Federation, 2014).

GlobalData epidemiologists utilized historical data obtained from peer-reviewed articles and reports to build the forecast for the diagnosed prevalent cases of T2D in the 9MM. GlobalData epidemiologists applied the prevalence of T2D drawn from the above sources to each country's population to calculate the prevalent cases T2D and major comorbidities of T2D, such as chronic kidney disease (CKD), cardiovascular disease (CVD), obesity, hypertension, dyslipidemia, and atherosclerosis in the diagnosed T2D prevalent population.

The following data describes the epidemiology of T2D. In the 9MM, GlobalData epidemiologists forecast an increase in the diagnosed prevalent cases of T2D from 164,826,095 diagnosed prevalent cases in 2018 to 212,237,385 diagnosed prevalent cases in 2028, with an annual growth rate (AGR) of 2.88% during the forecast period. India will have the highest number of diagnosed prevalent cases of T2D among the 9MM throughout the forecast period, while Spain will have the lowest. When examining the AGR of diagnosed prevalence of T2D in individual markets, GlobalData epidemiologists forecast that France will see the highest AGR of 5.60% during the forecast period, while Japan will show the lowest AGR of 0.39%.

Scope

  • The Type 2 Diabetes Epidemiology Report provides an overview of the risk factors and global trends of Type 2 Diabetes (T2D) in the nine major markets (9MM: US, France, Germany, Italy, Spain, UK, Japan, China, and India).
  • This report includes a 10-year epidemiological forecast for the diagnosed prevalent cases of T2D segmented by age, and sex. Additionally, the report provides a forecast for the prevalent cases of major comorbidities of T2D, such as chronic kidney disease (CKD), cardiovascular disease (CVD), obesity, hypertension, dyslipidemia, and atherosclerosis in the diagnosed T2D prevalent pool.
  • The T2D epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
  • The Epidemiology Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 9MM.

Reasons to buy

The T2D Epidemiology series will allow you to -

  • Develop business strategies by understanding the trends shaping and driving the global T2D market.
  • Quantify patient populations in the global T2D market to improve product design, pricing, and launch plans.
  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for T2D therapeutics in each of the markets covered.
  • Understand magnitude of T2D population by major comorbidities

1 Table of Contents

  • 1.1 List of Tables
  • 1.2 List of Figures

2 Type 2 Diabetes: Executive Summary

  • 2.1 Catalyst
  • 2.2 Related Reports
  • 2.3 Upcoming Reports

3 Epidemiology

  • 3.1 Disease Background
  • 3.2 Risk Factors and Comorbidities
  • 3.3 Global and Historical Trends
  • 3.4 Forecast Methodology
    • 3.4.1 Sources
    • 3.4.2 Forecast Assumptions and Methods: Diagnosed Prevalent Cases of T2D
    • 3.4.3 Forecast Assumptions and Methods: Prevalent Cases of CKD Among the Diagnosed Prevalent Cases of T2D
    • 3.4.4 Forecast Assumptions and Methods: Prevalent Cases of CVD Among the Diagnosed Prevalent Cases of T2D
    • 3.4.5 Forecast Assumptions and Methods: Prevalent Cases of Obesity Among the Diagnosed Prevalent Cases of T2D
    • 3.4.6 Forecast Assumptions and Methods: Prevalent Cases of Hypertension Among the Diagnosed Prevalent Cases of T2D
    • 3.4.7 Forecast Assumptions and Methods: Prevalent Cases of Dyslipidemia Among the Diagnosed Prevalent Cases of T2D
    • 3.4.8 Forecast Assumptions and Methods: Prevalent Cases of Atherosclerosis Among the Diagnosed Prevalent Cases of T2D
  • 3.5 Epidemiological Forecast for Type 2 Diabetes (2018-2028)
    • 3.5.1 Diagnosed Prevalent Cases of T2D
    • 3.5.2 Age-Specific Diagnosed Prevalent Cases of T2D
    • 3.5.3 Sex-Specific Diagnosed Prevalent Cases of T2D
    • 3.5.4 Comorbidities Among the Diagnosed Prevalent Cases of T2D
  • 3.6 Discussion
    • 3.6.1 Epidemiological Forecast Insight
    • 3.6.2 Limitations of the Analysis
    • 3.6.3 Strengths of the Analysis

4 Appendix

  • 4.1 Bibliography
  • 4.2 About the Authors
    • 4.2.1 Epidemiologist
    • 4.2.2 Reviewers
    • 4.2.3 Global Director of Therapy Analysis and Epidemiology
    • 4.2.4 Global Head and EVP of Healthcare Operations and Strategy
  • 4.3 About GlobalData
  • 4.4 Contact Us
  • 4.5 Disclaimer
Back to Top
전화 문의
F A Q